Medical Condition News

RSS

People with vitiligo may have less risk of developing malignant melanoma: Research

People with the skin pigmentation disorder vitiligo may have less risk of developing life-threatening malignant melanoma, according to new research. The study also further confirms the suspicion that vitiligo is an autoimmune disease, which occur when the body's immune system reacts against its own tissues or organs.

22 Apr 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

Positive results from initial clinical trial of ClariVein catheter

Results from the initial clinical trial of the ClariVein® catheter, used in a new minimally invasive treatment for varicose veins, have been announced. The device combines mechanical and chemical modalities to accomplish vein treatment in an in-office setting.

22 Apr 2010

Red wine consumption may protect brain from stroke damage, say Johns Hopkins researchers

Researchers at Johns Hopkins say they have discovered the way in which red wine consumption may protect the brain from damage following a stroke.

22 Apr 2010

FDA approves Medtronic's Complete SE Vascular Stent System for PAD

Broadening the scope of innovation for cardiovascular interventions beyond the heart, Medtronic, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the Complete® SE Vascular Stent System to be used for the treatment of peripheral arterial disease (PAD) in the iliac arteries, major blood vessels within the pelvis that supply blood to the lower extremities.

21 Apr 2010

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Icagen, Inc. today announced that results from a study of ICA-105665 in patients with photosensitive epilepsy will be presented at the Tenth Eilat Conference on New Antiepileptic Drugs on Tuesday, April 27, 2010 in Eilat, Israel. The presentation will be made by Dorothee Kasteleijn-Nolst Trenite, MD, University Medical Centre Utrecht and Universita di Roma Sapienza II, Rome, Italy.

21 Apr 2010

HemaQuest Pharmaceuticals closes $12M Series B financing

HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing compounds to treat sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of a $12M Series B financing led by new investor, Aberdare Ventures. HemaQuest's investor syndicate includes Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

21 Apr 2010

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures.

21 Apr 2010

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that data provided in a presentation entitled, "Antitumor activity of single small molecule agent targeting PI3K/mTor and HDAC," were presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010, which is being held in Washington, DC April 17-21.

21 Apr 2010

Researchers detect link between alcohol consumption, cancer and aging

Researchers have detected a link between alcohol consumption, cancer and aging that starts at the cellular level with telomere shortening.

21 Apr 2010

Sonic Innovations wins Best in Show award at AudiologyNOW! conference

Sonic Innovations, Inc. received a Best in Show award based on attendees' votes at the AudiologyNOW! conference for its tradeshow booth. The conference was held April 14 through 17 in San Diego, California and was attended by nearly 7,000 hearing care professionals.

21 Apr 2010

Path to Progress 5K Run/Walk to be hosted to benefit ABTA's research and patient-family programs

The American Brain Tumor Association will again host its annual Path to Progress 5K Run/Walk on Saturday, May 22, 2010 at Soldier Field in Chicago.

21 Apr 2010

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Hepatic fibrosis (HF) occurs in most types of chronic liver diseases and approximately 25%-40% of HF cases may ultimately progress to hepatic cirrhosis. Hepatic stellate cells (HSCs) contribute significantly to the occurrence of HF and the activation of HSC is the key issue in the pathogenesis of HF. Taurine is a kind of important anti-injury substance in the body.

21 Apr 2010

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

21 Apr 2010

BankAtlantic to join the families of Miami-Dade County in battle against cancer

BankAtlantic, Florida's Most Convenient BankSM announced today that it will join the families of Miami-Dade County in the battle against cancer. The 2010 American Cancer Society Relay for Life of Hialeah, also known as Relevo Por La Vida - Hialeah, gets underway Saturday, April 24, 2010 with teams of residents gathering at The City of Hialeah: Goodlet Park, located at 4200 West 8th Avenue in Hialeah.

21 Apr 2010

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

A clinical study underway at Rex Cancer Center of Wakefield will evaluate the use of telemonitoring in managing administration of Gleevec, a drug developed and manufactured by Novartis to treat chronic myeloid leukemia.

21 Apr 2010

Early tracheotomy does not reduce risk of VAP in mechanically ventilated adult ICU patients

Adult ICU patients who received tracheotomy 6 to 8 days vs. 13 to 15 days after mechanical ventilation did not have a significant reduction in the risk of ventilator-associated pneumonia, according to a study in the April 21 issue of JAMA.

21 Apr 2010

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled "TLE3 expression is predictive of response to chemotherapy in NSCLC," included 368 samples from carcinoma patients.

21 Apr 2010

Medical Condition News

People with vitiligo may have less risk of developing malignant melanoma: Research

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Positive results from initial clinical trial of ClariVein catheter

Red wine consumption may protect brain from stroke damage, say Johns Hopkins researchers

FDA approves Medtronic's Complete SE Vascular Stent System for PAD

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

HemaQuest Pharmaceuticals closes $12M Series B financing

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

Researchers detect link between alcohol consumption, cancer and aging

Sonic Innovations wins Best in Show award at AudiologyNOW! conference

Path to Progress 5K Run/Walk to be hosted to benefit ABTA's research and patient-family programs

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

New method to analyze molecular activity of cancer drugs for solid tumors using skin biopsies

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

BankAtlantic to join the families of Miami-Dade County in battle against cancer

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

Early tracheotomy does not reduce risk of VAP in mechanically ventilated adult ICU patients

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Latest News